Completed PHASE3 INTERVENTIONAL 3-arm NCT03755557

Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray

Demonstration of Therapeutic Equivalence/Non-inferiority as Well as Early Onset of Action of the Novel Water-soluble Budesonide Nasal Spray (Budesolv 10) Compared With Marketed Rhinocort® Aqua 64 in Patients Suffering From Grass Pollen Induced Allergic Rhinitis

Sponsor: Marinomed Biotech AG

Conditions Allergic Conjunctivitis Allergic Rhinitis Hayfever

Interventions Budesolv Placebo Rhinocort

Updated 7 times since 2018 Last updated: Oct 9, 2020 Started: Nov 19, 2018 Primary completion: Apr 5, 2019 Completion: Apr 5, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Allergic Conjunctivitis and Allergic Rhinitis, this trial is completed. The trial is conducted by Marinomed Biotech AG and has accumulated 7 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Nov 2020 — Jan 2021 [monthly]

Completed PHASE3
Sep 2019 — Nov 2020 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed

▶ Show 2 earlier versions

Feb 2019 — Sep 2019 [monthly]

Active Not Recruiting PHASE3

Status: Enrolling By Invitation → Active Not Recruiting
Dec 2018 — Feb 2019 [monthly]

Enrolling By Invitation PHASE3

First recorded

Nov 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Marinomed Biotech AG

Data source: Marinomed Biotech AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vienna, Austria